At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
MIRA Mira Pharma
Post-Mkt 08-26 16:34:52 EDT
0.7500
-0.0253
-3.26%
盘后0.7500
+0.00000.00%
16:10 EDT
High0.7741Low0.7500Vol27.21K
Open0.7701D1 Closing0.7753Amplitude3.11%
Mkt Cap31.41MTradable Cap26.21MTotal Shares41.88M
T/O20.74KT/O Rate0.08%Tradable Shares34.94M
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--

Loading ...

Mira Pharmaceuticals Q2 2026 Net Loss Narrows to $1.21 Million; Revenue Remains no Revenue
Reuters  ·  08-13
Mira Pharmaceuticals Q2 2026 Net Loss Narrows to $1.21 Million; Revenue Remains no Revenue
Mira Pharma Reports Positive 7-Day Dog Toxicokinetic Study Results for Obesity Drug Candidate SKNY-1
Reuters  ·  08-06
Mira Pharma Reports Positive 7-Day Dog Toxicokinetic Study Results for Obesity Drug Candidate SKNY-1
MIRA Pharmaceuticals Receives Nasdaq Minimum Bid Price Notice
TIPRANKS  ·  08-01
MIRA Pharmaceuticals Receives Nasdaq Minimum Bid Price Notice
Mira Pharmaceuticals Risks NASDAQ Delisting After Shares Fall Below $1 Bid Price Requirement
Reuters  ·  08-01
Mira Pharmaceuticals Risks NASDAQ Delisting After Shares Fall Below $1 Bid Price Requirement
Mira Pharmaceuticals provides update on MIRA-55, SKNY-1
TIPRANKS  ·  07-30
Mira Pharmaceuticals provides update on MIRA-55, SKNY-1
Mira Pharmaceuticals Advances Mira-55 Toward IND-enabling Studies After Completing Exploratory Tox Dosing in Rats, Dogs
Reuters  ·  07-30
Mira Pharmaceuticals Advances Mira-55 Toward IND-enabling Studies After Completing Exploratory Tox Dosing in Rats, Dogs
MIRA Pharmaceuticals Progresses MIRA-55 and SKNY-1 Toward IND-Enabling Studies
GlobeNewswire  ·  07-30
MIRA Pharmaceuticals Progresses MIRA-55 and SKNY-1 Toward IND-Enabling Studies
Mira Pharmaceuticals Announces Annual Shareholder Meeting
Reuters  ·  07-29
Mira Pharmaceuticals Announces Annual Shareholder Meeting
Mira Pharmaceuticals Oral Form Shows 'Positive' Results in Pre-Clinical Studies
MT Newswires Live  ·  07-10
Mira Pharmaceuticals Oral Form Shows 'Positive' Results in Pre-Clinical Studies
Mira Pharmaceuticals - Announces Positive Preclinical Results for Oral Mira-55 - SEC Filing
THOMSON REUTERS  ·  07-10
Mira Pharmaceuticals - Announces Positive Preclinical Results for Oral Mira-55 - SEC Filing
Mira Pharmaceuticals Announces Release of Mira-55 Oral Formulation Update
Reuters  ·  07-10
Mira Pharmaceuticals Announces Release of Mira-55 Oral Formulation Update
MIRA Reports Positive Preclinical Data for SKNY-1 Program
TIPRANKS  ·  07-06
MIRA Reports Positive Preclinical Data for SKNY-1 Program
Mira Pharmaceuticals reports SKNY-1 formulation results
TIPRANKS  ·  07-06
Mira Pharmaceuticals reports SKNY-1 formulation results
Mira Pharmaceuticals - Announces Positive Preclinical Results for Oral Skny-1 - SEC Filing
THOMSON REUTERS  ·  07-06
Mira Pharmaceuticals - Announces Positive Preclinical Results for Oral Skny-1 - SEC Filing
Mira Pharmaceuticals - Skny-1 Shows Favorable Bioavailability, Robust Brain and Liver Exposure, Once-daily Dosing Potential - SEC Filing
THOMSON REUTERS  ·  07-06
Mira Pharmaceuticals - Skny-1 Shows Favorable Bioavailability, Robust Brain and Liver Exposure, Once-daily Dosing Potential - SEC Filing
Mira Pharmaceuticals Reports Positive Preclinical Oral Formulation Results for Obesity, Addiction Drug Candidate Skny-1
Reuters  ·  07-06
Mira Pharmaceuticals Reports Positive Preclinical Oral Formulation Results for Obesity, Addiction Drug Candidate Skny-1
Mira Pharma Reports Preclinical Study Showing Mira-55 Reduces Anxiety-like Behavior, Differs from THC Mechanism
Reuters  ·  06-25
Mira Pharma Reports Preclinical Study Showing Mira-55 Reduces Anxiety-like Behavior, Differs from THC Mechanism
Mira Pharmaceuticals - Submits Phase 2a Clinical Trial Protocol to FDA for Ketamir-2 - SEC Filing
THOMSON REUTERS  ·  06-17
Mira Pharmaceuticals - Submits Phase 2a Clinical Trial Protocol to FDA for Ketamir-2 - SEC Filing
Mira Pharmaceuticals submits FDA Phase 2a trial protocol for Ketamir-2 in chemotherapy-induced neuropathy
Reuters  ·  06-17
Mira Pharmaceuticals submits FDA Phase 2a trial protocol for Ketamir-2 in chemotherapy-induced neuropathy
Mira Pharmaceuticals CFO Andriy Mushak files initial beneficial ownership statement
Reuters  ·  06-10
Mira Pharmaceuticals CFO Andriy Mushak files initial beneficial ownership statement

Introduction

Company Name.
Mira Pharma
Affiliated Markets:
NASDAQ
Listing Date:
--
Main Business:
MIRA Pharmaceuticals, Inc. operates as a clinical development stage biopharmaceutical company. The company focuses on the development and commercialization of a new molecular synthetic tetrahydrocannabinol (THC) analog under investigation for the treatment of adult patients with anxiety and cognitive decline typically associated with early-stage dementia. It is developing MIRA1a, a synthetic cannabinoid analog to treat anxiety and chronic pain by targeting the cannabinoid type 1 and type 2 receptors. The company was formerly known as MIRA1a Therapeutics, Inc. MIRA Pharmaceuticals, Inc. was incorporated in 2020 and is headquartered in Baltimore, Maryland.
Issue price:
--